Lupin Launches Rivaroxaban Generic in US
x
Lupin launches Rivaroxaban for Oral Suspension (generic Xarelto) in the US. Treats VTE in pediatric patients. Annual sales: USD 11M.
New Delhi, Oct 1 (PTI) Drug maker Lupin on Wednesday said it has launched an anticoagulant medication in the US.
The company has launched Rivaroxaban for Oral Suspension (1 mg/mL), a generic version of Janssen Pharmaceuticals, Inc.'s Xarelto for Oral Suspension, in the US, the drug maker said in a statement.
Rivaroxaban for Oral Suspension is indicated for the treatment of venous thromboembolism (VTE) and the reduction in the risk of recurrent VTE in pediatric patients.
It is also indicated for the treatment of thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure.
As per IQVIA MAT July 2025 data, Rivaroxaban for Oral Suspension, 1 mg/mL, had estimated annual sales of USD 11 million in the US.
The company has launched Rivaroxaban for Oral Suspension (1 mg/mL), a generic version of Janssen Pharmaceuticals, Inc.'s Xarelto for Oral Suspension, in the US, the drug maker said in a statement.
Rivaroxaban for Oral Suspension is indicated for the treatment of venous thromboembolism (VTE) and the reduction in the risk of recurrent VTE in pediatric patients.
It is also indicated for the treatment of thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure.
As per IQVIA MAT July 2025 data, Rivaroxaban for Oral Suspension, 1 mg/mL, had estimated annual sales of USD 11 million in the US.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Spright Agro
- 0.70 (+ 4.48)
- 110120075
- Vodafone Idea L
- 9.61 (+ 3.67)
- 84379834
- Murae Organisor
- 0.28 (+ 3.70)
- 35538309
- Sunshine Capital
- 0.28 (+ 3.70)
- 26912524
- Suzlon Energy Ltd.
- 57.39 ( -3.76)
- 14790944
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback